PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Foreign entity interest: GRIFOLS S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE BIRKOFER | — |
| THOMAS B LILBURN | — |
| DANIEL SEATON | — |
Health Issues HCR
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Foreign entity interest: GRIFOLS S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE BIRKOFER | — |
| THOMAS B LILBURN | — |
| DANIEL SEATON New | n/a |
Taxation/Internal Revenue Code TAX
Issues related to the continuation or change of the Orphan Drug Tac Credit.
Foreign entity interest: Grifols S.A.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS B LILBURN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.